Context: Despite tremendous interest in hypoparathyroidism, large cohort studies describing
typical treatment patterns, laboratory parameters, and rates of complications are lacking. …

Background Current approaches to diagnosing testosterone deficiency do not consider the
physiological consequences of various testosterone levels or whether deficiencies of …

Background Unlike most chronic diseases, osteoporosis treatments are generally limited to
a single drug at a fixed dose and frequency. Nonetheless, no approved therapy is able to …

Background Osteoporosis medications increase bone-mineral density (BMD) and lower but
do not eliminate fracture risk. The combining of anabolic agents with bisphosphonates has …

Context: Aging is associated with declining gonadal steroid production, low bone mineral
density (BMD), and fragility fractures. The efficacy and safety of testosterone replacement in …

Fibroblast growth factor 23 (FGF23) promotes phosphaturia and suppresses 1,25‐dihydroxyvitamin
D [1,25(OH) 2 D] production. PTH also promotes phosphaturia, but, in contrast, …

Objective Vitamin D deficiency is highly prevalent in high-risk patient populations, but the
prevalence among otherwise healthy adults is less well-defined. The goal of this study was to …

The Study of Women’s Health Across the Nation (SWAN) has significantly added to understanding
of changes in women’s bone health over the menopause transition (MT), advancing …

Context: Current osteoporosis medications increase bone mineral density (BMD) modestly
and reduce, but do not eliminate, fracture risk. Attempts to improve efficacy by administering …

Objective To assess the effects of sustained aromatase inhibition in older hypogonadal men.
Design and patients In a 1‐year randomized, double‐blind, placebo‐controlled trial, 88 men…